Margherita Dell’aNno

Margherita Dell’aNno

Auto-generated profile, based on publicly available information

Margherita Dell’aNno

Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PTPatrizia Tornabene
Patrizia Tornabene
RFRita Ferla
Rita Ferla
MLManel Llado-Santaeularia
Manel Llado-Santaeularia
MCMiriam Centrulo
Miriam Centrulo
MDMargherita Dell’aNno
Margherita Dell’aNno
AAAlberto Auricchio
Alberto Auricchio
Challenges to the widespread application of gene therapy with adeno-associated viral (AAV) vectors include dominant conditions due to gain-of-function mutations which require allele-specific knockout, as well as long-term transgene expression from proliferating tissues, which is hampered by AAV DNA episomal status. To overcome these challenges, we used CRISPR/Cas9-mediated homology-independent targeted integration (HITI) in retina and liver as paradigmatic target tissues. We show that AAV-HITI targets photoreceptors of both mouse and pig retina, and this results in significant improvements to retinal morphology and function in mice with autosomal dominant retinitis pigmentosa. In addition, we show that neonatal systemic AAV-HITI delivery achieves stable liver transgene expression and phenotypic improvement in a mouse model of a severe lysosomal storage disease. We also show that HITI applications predominantly result in on-target editing. These results lay the groundwork for the application of AAV-HITI for the treatment of diseases affecting various organs.